健择在36例期食管癌术后辅助化疗中的应用

Gemecitabine in the treatment of Ⅲ Stage esophageal cacinoma postoperation

目的 探讨 期食管癌术后辅助化疗的方案。方法 2 0 0 1年 1月至 2 0 0 2年 9月 36例 期食管癌术后以健择联合顺铂方案辅助化疗 ,观察其对 1年生存率、局部复发及远处转移的影响 ,并按 WHO毒性反应分级标准评价毒副反应。结果 36例 1年生存率 84 % ,同期 期食管癌单纯手术 1年生存率 6 0 .6 % ,有显著差异 (P<0 .0 5 ) ;2例吻合口复发癌及 6例远处转移的平均时间为 9.5月及 12 .7月 ;毒副反应以血液系统及消化系统毒性为主 ,耐受性良好。结论 健择联合顺铂方案在 期食管癌术后辅助化疗方面值得进一步研究。

Objective ]To explore and evaluate the clinical efficacy and toxicity of gemecitabine-cisplatin combination in the assistant treatment of Ⅲ stage esophageal carcinom postoperation.To explore and evaluate the clinical efficacy and toxicity of gemecitabine-cisplatin combination in the assistant treatment of Ⅲ stage esophageal carcinom postoperation. From January 2001 to March 2002,in our hospital there were 36 cases of Ⅲ stage esopgeal carcinoma postoperation treated with gemecitabine-cisplatin combination.The toxicity and one year survival rate were observed and evaluated. The one year survival rate of all 25 case was 84%.the one year survival rate of Ⅲ stage esopgeal carcinoma treated only by operation was 60.6% in the same period,there were significantly different(P<0.05).Up to now there were 2 cases with anastomotic carcinoma recurrance and 2 cases with distant metastasis in all visited patients afterwards.The toxicity was most common in leukopenia and digestive synstem and tolerable.[Conclusion] The gemecitabine and cisplatin combination regime is effective in the assistant treatment of Ⅲ stage esophageal carcinom postoperation.It is worth recommending and further studying.